生物科技公司Beam Therapeutics(BEAM)股价今日盘中大涨6.32%,报28.43美元。市场分析人士认为,此轮涨势或与公司基因编辑技术的发展前景获市场看好有关。
作为一家基因编辑领域的创新公司,Beam Therapeutics利用自主研发的碱基编辑技术,可在不引起DNA双链断裂的情况下,精准编辑基因组中的单个碱基。该技术或有望实现基因校正、修饰、激活、沉默等多种应用,为创制新型基因药物提供了新的技术路径。
公司目前管线中包括多个针对各类遗传性疾病的在研项目,如BEAM-101用于治疗sicklecell病和β地中海贫血症、BEAM-302用于治疗α1抗酵素缺陷性肝病等。随着在研产品的持续推进,预计未来一段时间内将陆续有重要临床数据公布,这可能是推动公司股价上涨的利好因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.